Copertina

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Anna de Dios, Neus Pagès‐Puigdemont, Sergio Ojeda, Pau Riera, Rebeca Pelegrín, Noemí Morollon, Robert Belvís, Jordi Real, Montserrat Masip
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
di: Irina Krikova, et al.
Pubblicazione: (2024)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
di: Christoph T. Berger, et al.
Pubblicazione: (2026)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
di: Marta Pascual‐Mato, et al.
Pubblicazione: (2024)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
di: Alex Jaimes, et al.
Pubblicazione: (2024)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
di: Yunzhu Tang, et al.
Pubblicazione: (2025)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
di: María Clara García‐Castillo, et al.
Pubblicazione: (2026)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
di: Tzu‐Hsuan Su, et al.
Pubblicazione: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
di: Zoe Tasma, et al.
Pubblicazione: (2025)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
di: Eric A. Kaiser, et al.
Pubblicazione: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
di: Alex Harlan, et al.
Pubblicazione: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
di: David Croteau, et al.
Pubblicazione: (2026)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Gabriel Gárate, et al.
Pubblicazione: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Ann I. Scher, et al.
Pubblicazione: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
di: Julia Peris‐Subiza, et al.
Pubblicazione: (2025)

Deep brain stimulation for chronic refractory cluster headache: A case series about long‐term outcomes and connectivity analysis
di: Juan Ángel Aibar‐Durán, et al.
Pubblicazione: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
di: Andrew C. Charles, et al.
Pubblicazione: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
di: Christopher C. Anderson, et al.
Pubblicazione: (2024)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Afterimage duration differs for migraine with or without aura
di: Florian Rimmele, et al.
Pubblicazione: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
di: Rebecca Erwin Wells, et al.
Pubblicazione: (2024)

Useful considerations for treating migraine in patients with autism
di: Sinifunanya E. Nwaobi
Pubblicazione: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
di: Gabriel Camargo de Oliveira, et al.
Pubblicazione: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
di: Inga Zalia Tummoszeit, et al.
Pubblicazione: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Counting the cost: How migraine shapes lives and economies
di: Risako Shirane, et al.
Pubblicazione: (2025)

Cardiovascular risk and triptan usage among patients with migraine
di: Ido Peles, et al.
Pubblicazione: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
di: Shiri Shinan‐Altman, et al.
Pubblicazione: (2026)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
di: Chay Ngee Lim, et al.
Pubblicazione: (2025)